Acetyl-l-Carnitine and New-Onset Psychosis During the COVID-19 Pandemic

Dhir, Sakshi; Khalid, Zaira; Salcedo, Jisselly; Shanbour, Alaa

doi:10.4088/pcc.20l02804

Prim. Care Companion CNS Disord.

2020

DOI: 10.4088/pcc.20l02804

|View full text |Cite

Acetyl-l-Carnitine and New-Onset Psychosis During the COVID-19 Pandemic

Sakshi Dhir

Zaira Khalid

Jisselly Salcedo

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(Continued )Servén et al, 2021). Some patients presented features complicating diagnosis: On two occasions(Dhir et al, 2020;Ambar Akkaoui et al, 2021), self-treatment with different drugs might have contributed to psychosis. Cannabis consumption with low intensity was reported in one case(Marouda et al, 2021), with high intensity in two cases(Doufik et al, 2021;Marín et al, 2021).…”

mentioning

confidence: 99%

First-episode psychotic disorders in the wake of the COVID-19 pandemic: a descriptive review of casereports

Rittmannsberger¹,

Barth²,

Malík³

et al. 2022

Acta Neuropsychiatr.

View full text Add to dashboard Cite

Objective: Since the onset of COVID-19 pandemic many case reports and case series dealt with new onset psychotic disorders in patients either infected with SARS-CoV-2 or thematically linked to the pandemic, but without an infection. Our aim was to provide a comprehensive collection of these reports to illustrate the nature of these psychoses. Methods: We conducted a literature search in Medline, EMBASE, PSYCHINFO, using search terms regarding first episode psychotic disorders in the context of corona. Results: 96 case reports or case series covering 146 patients (62 without and 84 with SARS-CoV-2 infection) were found. Compared to patients without infection, patients with infection showed significantly more often visual hallucinations (28.6% vs 8.1%), confusion (36.9% vs 11.3%), an acute onset of illness (88.5% vs 59.6%) and less often depression (13.1% vs 35.5%) and a delusional content related to the pandemic (29.5% vs 78.3%). Both groups had an equally favourable outcome with a duration of psychosis ≤2 weeks in half and full remission in two thirds of patients. In patients with infection signs of inflammation were reported in 78.3% and increased CRP in 58.6%. While reports on patients with infection are continuously published, no report about patients without infection was found after July 2020. Conclusion: Cases without infection were considered reactive and originated all from the first wave of the Corona pandemic. In cases with infection, inflammation was considered as the main pathogenetic factor but was not found in all patients. Diagnosis was impeded by the overlap of psychosis with delirium.

show abstract

mentioning

confidence: 99%

First-episode psychotic disorders in the wake of the COVID-19 pandemic: a descriptive review of casereports

Rittmannsberger¹,

Barth²,

Malík³

et al. 2022

Acta Neuropsychiatr.

View full text Add to dashboard Cite

show abstract

Levacecarnine

2021

Reactions Weekly

View full text Add to dashboard Cite

Psychosis: case reportA 56-year-old man developed psychosis during off label treatment with levacecarnine for improving his immune system and energy levels during the COVID-19 pandemic [routes, dosages and time to reaction onset not stated].The man presented to hospital due to disorganized thought process, racing thoughts and paranoid delusions of drones following him. He was admitted. On admission, a head CT did not reveal any abnormalities. Laboratory tests including rapid plasma regain, vitamin-B12, HIV, folate and urine drug screen did not reveal any medical cause of his psychiatric condition. He reported that he had brought an online supplement containing high doses of levacecarnine [acetyl-L-carnitine] and ingredients of multivitamin to improve his immune system and energy levels during the COVID-19 pandemic. His symptoms had started a few days after taking the supplement. However, the true ingredients could not be confirmed as the supplement not being approved. Before using levacecarnine, he was functional and running his own health-related business.The man was treated with risperidone and was discharged home after return to his baseline level of functioning.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Acetyl-l-Carnitine and New-Onset Psychosis During the COVID-19 Pandemic

Cited by 2 publications

References 0 publications

First-episode psychotic disorders in the wake of the COVID-19 pandemic: a descriptive review of casereports

First-episode psychotic disorders in the wake of the COVID-19 pandemic: a descriptive review of casereports

Levacecarnine

Contact Info

Product

Resources

About